
Financials
Five years in figures
2021 | 2020 | 2019 | 2018 | 2017 | ||
Net sales | EUR million | 1,254.3 | 1,116.2 | 1,090.4 | 1,118.5 | 1,185.5 |
of which outside Finland | EUR million | 1,142.0 | 1,021.9 | 977.5 | 1,006.6 | 1,073.1 |
in percent of net sales | % | 91.0 | 91.5 | 89.6 | 90.0 | 90.5 |
export from Finland | EUR million | 24.2 | 20.1 | 20.2 | 19.5 | 22.8 |
Change of net sales, % | % | 12.4 | 2.4 | -2.5 | -5.6 | -1.6 |
Gross profit | EUR million | 539.8 | 452.0 | 447.3 | 485.1 | 512.2 |
% of net sales | % | 43.0 | 40.5 | 41.0 | 43.4 | 43.2 |
EBIT |
EUR
million |
142.8 | 98.0 | 60.1 | 91.6 | 97.9 |
% of net sales | % | 11.4 | 8.8 | 5.5 | 8.2 | 8.3 |
Comparable EBIT |
EUR
million |
154.2 | 109.0 | 77.7 | 109.3 | 103.7 |
% of net sales | % | 12.3 | 9.8 | 7.1 | 9.8 | 8.7 |
EBITA | EUR million | 157.4 | 125.8 | 72.9 | 112.5 | 113.2 |
% of net sales | % | 12.5 | 11.3 | 6.7 | 10.1 | 9.5 |
Comparable EBITA | EUR million | 168.8 | 136.8 | 90.6 | 121.7 | 119.0 |
Change in fair value of biological assets | EUR million | 1.3 | 0.7 | -0.2 | 2.0 | 0.7 |
Financial items net | EUR million | 0.0 | -8.9 | 3.4 | 9.4 | 119.3 |
% of net sales | % | 0.0 | -0.8 | 0.3 | 0.8 | 10.1 |
Profit before taxes | EUR million | 144.1 | 89.8 | 63.2 | 103.0 | 217.8 |
% of net sales | % | 11.5 | 8.0 | 5.8 | 9.2 | 18.4 |
Income tax | EUR million | -56.5 | -21.3 | -10.8 | 21.1 | -50.8 |
Profit for the period attributable to the equity
holders in the parent company |
EUR million | 86.6 | 67.6 | 51.7 | 81.6 | 166.4 |
% of net sales | % | 6.9 | 6.1 | 4.7 | 7.3 | 14.0 |
Non-controlling interests | EUR million | 0.9 | 0.8 | 0.7 | 0.2 | 0.7 |
Employee benefits | EUR million | 293.7 | 262.9 | 311.9 | 307.9 | 315.3 |
Depreciation, amortization and impairment | EUR million | 61.6 | 76.1 | 59.6 | 43.8 | 38.8 |
% of net sales | % | 4.9 | 6.8 | 5.5 | 3.9 | 3.3 |
Cash flow from operating activities | EUR million | 122.9 | 199.2 | 96.5 | 105.9 | 103.8 |
Capital expenditure | EUR million | 34.4 | 30.0 | 40.0 | 46.2 | 32.8 |
% of net sales | % | 2.7 | 2.7 | 3.7 | 4.1 | 2.8 |
Research and development costs in income statement | EUR million | 15.5 | 16.5 | 18.4 | 18.4 | 18.8 |
% of net sales | % | 1.2 | 1.5 | 1.7 | 1.6 | 1.6 |
Capitalized development costs | EUR million | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Equity attributable to equity holders of the parent company | EUR million | 812.1 | 757.8 | 760.9 | 1,207.0 | 1,269.4 |
Non-controlling interest | EUR million | 4.2 | 3.8 | 3.6 | 2.7 | 2.8 |
Equity total | EUR million | 816.3 | 761.6 | 764.5 | 1,209.7 | 1,272.1 |
Net interest-bearing debt | EUR million | 144.4 | 143.7 | 261.1 | 135.4 | 147.7 |
Working capital | EUR million | 164.5 | 134.2 | 194.4 | 197.0 | 195.9 |
Balance sheet total | EUR million | 1,435.5 | 1,342.0 | 1,364.3 | 1,719.2 | 1,837.9 |
Return on investment | % | 15.3 | 9.9 | 6.0 | 7.9 | 15.4 |
Return on equity | % | 11.1 | 9.0 | 5.3 | 6.6 | 13.4 |
Equity ratio | % | 56.9 | 56.8 | 56.0 | 70.4 | 69.3 |
Net gearing | % | 17.7 | 18.9 | 34.2 | 11.2 | 11.6 |
Personnel (FTE), average | 6,081 | 6,104 | 6,840 | 7,304 | 7,709 | |
Personnel, end of period | 6,690 | 6,411 | 6,984 | 7,706 | 7,932 | |
of which outside Finland | 5,579 | 5,348 | 5,852 | 6,581 | 6,806 |